Innovations and Challenges in Prostate Cancer: Defining and Treating "High Risk" Disease
Fifth Cambridge Conference
November 2005
Recommendations for Defining and Treating High Risk Localized Prostate Cancer
IM Thompson, PR Carroll, MA Carducci
Identifying Men Diagnosed with Clinically Localized Prostate Cancer Who Are at High Risk for Death from Prostate Cancer
AV D'Amico, M Hui-Chen, AA Renshaw, B Sussman, KA. Roehl, WJ Catalona
Defining High Risk Prostate Cancer with Risk Groups and Nomograpms: Implications for Designing Clinical Trials
M Roach III, V Weinberg, M Nash, HM Sandler, PW McLaughlin, and MW Kattan
Defining High Risk Prostate Cancer - Where Do We Set the Bar?
A Translational Science Approach to Risk Stratification.
IM Thompson
Initial therapy with radical prostatectomy for high risk, localized prostate cancer
JE Montie
The Case for Adjuvant Therapy of Prostate Cancer
LM Glodé
Management of Locally Advanced Prostate Cancer: Past, Present, Future
GP Swanson
The Case for Systemic Therapy Alone
C Sweeney
Case for androgen deprivation as primary therapy in early stage disease: results from J-CaP and CaPSURE
H Akaza, S Hinotsu, M Usami, O Ogawa, S Kagawa, T Kitamura, T Tsukamoto, S Naito, Y Hirao, M Murai, H Yamanaka, M Namiki
Bone-related Events in High Risk Prostate Cancer
S Srinivas and N Colocci
Management of High Risk Metastatic Prostate Cancer: Defining Risk at the Time of Initial Treatment Failure
SS Chang
High-Risk Biochemical Relapse and the Timing of Androgen Deprivation Therapy
EJ Small and CJ Ryan
The Case for Early Chemotherapy for the Treatment of Metastatic Disease
A Lucas and DP Petrylak
The Case for Secondary Hormonal Therapies in the Chemotherapy Age
EJ Small and CJ Ryan
Management of High Risk Metastatic Prostate Cancer: The Case for Novel Therapies
TC Brand and A Tolcher
